Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release


BBS-Bioactive Bone Substitutes Oyj
Posted on: 08 Mar 18

BBS-Bioactive Bone Substitutes Plc, Company Announcement 8.3.2018 AT 12:00


The shareholders of BBS-Bioactive Bone Substitutes Plc are invited to the company's Annual General Meeting, which is held at the company's premises at Kiviharjunlenkki 6, 90220 Oulu, on Thursday 29 th March 2018 starting at 1.00 pm . At the AGM the right to participate and the right to vote are held by the shareholders registered in the shareholder register on the record date 19 th March 2018.


  1. Opening of the AGM
  2. Election of the chairman and the secretary
  3. Election of person to scrutinize the minutes and persons to supervise the counting of votes
  4. Recording the legality of the meeting
  5. Recording  the attendance at the meeting  and adoption  the list of votes
  6. Presentation of the annual accounts, the report of the Board of Directors and the auditor's report for the year 2017

CEO's Review

  1. Adoption of the annual accounts
  2. Resolution on the use of the profit shown on the balance sheet and the payment of dividends

The Board of Directors proposes that the result for the financial year be transferred to the previous profit and loss account and no dividend is distributed

  1. Resolution on the discharge of the members of the Board of Directors and the President and CEO from liability
  2. Resolution  on the remuneration of the members of the Board of Directors
  3. Resolution on the number of members of the Board of Directors
  4. Election of the members of the Board of Directors
  5. Resolution  on the auditors remuneration
  6. Election of the auditor
  7. Authorizing the Board to decide on the issuance of shares and the issuance of special rights entitling to shares .

The Board proposes to the AGM at 29 th May 2018 at 1.00 pm that the Board be authorized to decide on the issuance of the shares. The proposed authorization includes the right to deviate from the shareholders' pre-emptive rights, provided that the Company has a weighty financial reason to do so.

A share issue may be executed by increasing a share capital by a new subscription, by convertible bonds or by issuing stock options in one or more installments under the following terms:

The Board is authorized to decide to increase the share capital by issuing a share issue, issuing a convertible loan, or issuing stock options in one or more installments. In the new issue or alternatively, convertible loans or stock options may entitle to subscribe for a maximum of 1.000.000 (one million) new shares. The company currently has 5.090.520 shares. The old authorization is proposed to be cancelled.

The authorization includes the right to deviate from the shareholders' pre-emptitive right to subscribe for new shares, convertible loans or warrants and to decide on the subscription prices, subscription rights and subscription terms. The subscription price of the shares is recorded in the invested unrestricted equity fund. The authorization may be used in deviation from shareholder's pre-emptitive subscription right, provided that there is a weighty financial reason for the company, such as the extension of the company's shareholder base or another essential business interest or an arrangement to safeguard financial liquidity. . Under the authorization, shares may be offered in deviation from shareholder's pre-emptitive rights to the related party but not for the benefit of related parties. The Board is entitled to decide that shares can be subscribed for against payment of assets, by set off of a receivable or otherwise on specific terms. Possible options are used at the discretion of the Board. The authorization is valid until the next AGM but up to June 30 th 2019.

  1. Closing of the meeting


The financial statements and the auditor's report are available to shareholders at the company's premises at Kiviharjunlenkki 6, 90220 Oulu. Copies of the documents will be sent to shareholders on request.


1. Shareholders listed in the shareholder register
The right to attend the AGM will be on each shareholder who, on the record date of March 19th 2018 of the AGM, is registered in the company's shareholder register maintained by Euroclear Finland Oy. A shareholder whose shares are subscribed to his or her personal Finnish book-entry account is registered in the company's shareholder register.

A shareholder registered in the Company's Shareholder Register who wishes to attend the AGM must register to the AGM via e-mail at the following address or by post to Kiviharjunlenkki 6, 90220 Oulu. The registration must be received by March 26th 2018 at the latest 10.00 am.

When registering, the name of the shareholder, social security number or company-ID, the telephone number and the identity of the potential assistant should be indicated. The disclosure of the personal data of the shareholders to BBS Plc is only used in connection with the AGM and the related necessary registration.

A shareholder, his representative or agent, at the meeting venue, should be able to prove his/her identity and/or the right to represent, where appropriate.

2. Holders of nominee-registered shares

The shareholders of nominee-registered shareholder are entitled to attend at AGM on the basis of the shares entitling him/her to be registered in the Shareholder Register maintained by the Euroclear Finland Oy on 19 th March 2018. Participation also requests the shareholder to be temporarily entered into the shareholder register maintained by Euroclear Finland Oy by March 26 th 2018 at 10:00 am on the basis of these shares. As regards the shares subscripted to in the temporary register of nominee-register of shareholders, this is considered to be registered for the AGM.

The owner of a nominee-registered shareholder is advised to request promptly from his/her custodian the necessary instructions for registration in the company's temporary shareholder register on the issuance of power of attorney and registration for the AGM. The administrator of the custodian shall notify such shareholder of nominee-registered shares who wishes to attend the AGM to be included in the company's temporary shareholder register no later than on the above-mentioned date.

3. The use of agent and proxies

A shareholder may participate in the AGM and exercise his/her rights there through an agent. The shareholder's agent must prove his identity and present dated power of attorney or otherwise provide in a reliable manner that he/she is entitled to represent the shareholder at the AGM. If a shareholder participates in the AGM through multiple agents, representing the shareholder in several securities accounts, at the time of registration must be reported the shares on the basis of which each representative represents the shareholder. Possible proxy documents are requested to be delivered by e-mail to or by letter to Kiviharjunlenkki 6, 90220 Oulu of March 26 th 2018 at 10:00 am. The registration must be received by March 26 th 2018 at the latest 10.00 am.

In Oulu March 7 th 2018

BBS-Bioactive Bone Substitutes Plc

Board of Directors


Further enquiries:

Pekka Jalovaara, CEO,
tel. +358 50 5529275, e-mail:  

Hannu Säynäjäkangas, CFO,
tel. +358 40 5021092, e-mail:

Certified Advisors:
First North Finland: Aalto Capital Partners Oy, tel. +358 40 5477 000
First North Sweden: Stockholm Certified Advisers AB, tel. +46 70 5516 729

Nasdaq Helsinki Ltd
Nasdaq Stockholm Ltd

Main media


BBS-Bioactive Bone Substitutes Plc  ("BBS") is the health technology company operating since  2003. Before that there was a background of seven years of product development in the University of Oulu. We have developed a new product for healing of difficult bone fractures and for solving the problems in bone healing. Our mission is to offer new generation medicinal products for the orthopedic surgery. The research and development in the field of medicine requires perseverance and courage to develop new things.  We have over 20 years of expertise in this. Our operations are characterised by top expertise, innovativeness and dedicated and committed employees. The ARTEBONE ®product is ready and the application process for the CE-mark has been initiated. BBS is the company having its headquarters in Oulu. We have our own production plant located in Reisjärvi and it is approved by FIMEA. More information:

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: BBS-Bioactive Bone Substitutes Oyj via GlobeNewswire

Last updated on: 09/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.